Executive leadership at Nexalin Technology.
Board of directors at Nexalin Technology.
Research analysts covering Nexalin Technology.
Recent press releases and 8-K filings for NXL.
Nexalin Technology Launches NeuroCare® Virtual Clinic Platform
NXL
Product Launch
New Projects/Investments
- Nexalin Technology, Inc. (NXL) launched its new AI-designed virtual clinic platform, NeuroCare®, in collaboration with the University of California, San Diego.
- The platform is designed to increase patient access, reduce costs, and provide long-term physician-patient care and monitoring for conditions including Alzheimer’s/dementia, mood disorders, and military-related conditions such as TBI and PTSD.
- NeuroCare® is integrated with Nexalin’s new Gen-3 HALO™ headset and operates on a subscription-based business model, aiming for sustainable revenue and long-term patient outcomes.
1 day ago
Nexalin Technology Receives Nasdaq Minimum Bid Price Deficiency Notification
NXL
Delisting/Listing Issues
- Nexalin Technology, Inc. (NXL) received a deficiency letter from Nasdaq on January 21, 2026, indicating non-compliance with the $1.00 per share minimum bid price requirement for continued listing.
- The company has 180 calendar days, until July 20, 2026, to regain compliance by achieving a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days.
- This notification has no immediate effect on the company's listing status, and its shares will continue to trade on The Nasdaq Capital Market.
- Nexalin Technology is not considering a reverse stock split at this time to address the deficiency.
Jan 23, 2026, 10:20 PM
Nexalin Technology Announces Positive Clinical Study Results for ADHD Treatment
NXL
Product Launch
New Projects/Investments
- Nexalin Technology announced the publication of a peer-reviewed clinical study demonstrating its Deep Intracranial Frequency Stimulation (DIFS™) technology significantly improved attention and normalized brain activity in adult patients with Attention Deficit Hyperactive Disorder (ADHD).
- The randomized, double-blind, sham-controlled trial showed participants receiving active treatment achieved a 10.1-point average improvement on the Adult ADHD Self-Report Scale, compared to a 5.5-point improvement in the sham group, representing a 4.6-point separation.
- Advanced neuroimaging, including magnetoencephalography (MEG), validated the improvements by showing reductions in excessive gamma-frequency brain activity and improved communication across key brain networks.
- The treatment was well tolerated, with a safety profile comparable to sham stimulation and no serious adverse events reported.
Jan 14, 2026, 2:00 PM
Nexalin Technology, Inc. Updates Investors on Product Development and Financials
NXL
Product Launch
New Projects/Investments
Guidance Update
- Nexalin Technology, Inc. filed an 8-K on December 5, 2025, providing an updated Investor Presentation on its strategy for advanced frequency neurostimulation to improve mental health.
- The company is developing its Deep Intracranial Frequency Stimulation (DIFS®) technology with Gen 2 - SYNC for in-clinic use and Gen 3 - HALO for in-home virtual clinics, with FDA clinical trials for Gen 2 beginning in the USA in 2025 and a Gen 3 FDA application expected in 2026.
- Nexalin is collaborating with the FDA on a De Novo clinical treatment application for indications including Insomnia, Alzheimer’s & Dementia, TBI/PTSD, Depression, Anxiety, Addiction, and Chronic Pain.
- As of September 30, 2025, the company reported $4.4 million in cash and equivalents and $0 debt, with a business model focused on device sales and recurring revenue from electrodes and subscriptions in the $60 billion global mental health market.
Dec 5, 2025, 10:05 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more